Document is current
Any future updates will be listed below
-
Authors
Hagman, Emilia
Halsteinli, Vidar
Putri, Resthie R.
Hansen Edwards, Christina
Waaler Bjørnelv, Gudrun
Marcus, Claude
Ødegård, Rønnaug A.
-
Funding
Funding for this research was provided by:
Åke Wiberg Stiftelse (M22-0183)
Center for Innovative Medicine (FoUI-988950)
Ollie and Elof Ericsson’s foundation
Stiftelsen Frimurare Barnhuset i Stockholm
Norges Forskningsråd (344375, 295989)
Kreftforeningen (208164)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 13 January 2025
First Online: 21 January 2025
Declarations
:
: An opt-out approval was required from the patient/guardian to record data in the Swedish Childhood Obesity Treatment Register. The regional Ethics Committee in Stockholm, Sweden, approved the study (No. No. 2016/922–31/1, 2020–02707). For the HUNT cohort all participants consented to the use of their data and the present study was approved by the Regional Committee of Ethics in Medical Research (2016/537).
: Not applicable.
: EH reports commissioned research for Novo Nordisk (2023), but not for the current study; honoraria for lectures for Novo Nordisk; a leadership or fiduciary role on scientific/medical committee: Member of the steering committee for the Swedish Childhood Obesity Treatment Register. CM reports consulting fees from Novo Nordisk,Rhythm, Oriflame Wellness, DeFaire Medical, and Evira AB; honoraria for lectures from Novo Nordisk, Oriflame Wellness, and AstraZeneca; payment for expert testimony from Novo Nordic Foundation and Rhythm; leadership or fiduciary role on scientific/medical committee: board member of European Society for Paediatric Endocrinology (ESPE) Obesity working group, board member of the Swedish Pediatric Obesity Society, and Register holder for the Swedish Childhood Obesity Treatment Register. RRP, VH, CHE, MWB and RAØ declare no competing interests.
